Advanced Filters
noise

Chicago, Illinois Clinical Trials

A listing of Chicago, Illinois clinical trials actively recruiting patient volunteers.

Found 1,637 clinical trials
A Anna Somera

Assessment of CSF Shunt Flow and Headaches With a Thermal Measurement Device

This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow over multiple measurements performed by a study subject during headache and non-headache periods.

6 - 80 years of age All Phase N/A
P Pablo Fernandez-Penas, MD

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, …

12 - 65 years of age All Phase 1
E Erin Lonergan, MS

CCHS Secure Health-hub Advancing Research Efforts (CCHS SHARE)

The purpose of this study is to capture longitudinal natural history data in Congenital Central Hypoventilation Syndrome (CCHS). This will include capturing standardized clinical data from standard of care assessments at several CCHS referral centers. Funding source-FDA OOPD

years of age All Phase N/A
M Monica Perez, PhD, PT

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.

18 - 85 years of age All Phase 1/2
S Shelley Coughlin

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive). In addition, a parallel cohort of participants ages 13 to \<16 will receive open-label MRM-3379. All participants will …

13 - 45 years of age Male Phase 2
M Mary Hannan

Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD

Fight Fatigue is evaluating the feasibility and acceptability of a combined progressive muscle relaxation and walking intervention to reduce fatigue for adults with end-stage kidney disease receiving in-center hemodialysis.

18 years of age All Phase N/A
V Vishakha Nanda, MD

Impact of Serial Bedside Video Calls on Stress Level in Parents of Infants Admitted to NICU

The goal of this randomized prospective interventional study is to determine if serial bedside video calls w/audio feature to NICU parents in addition to the routine phone and/or bedside updates can reduce parental stress level. The main question it aims to answer is if the impact of audio-visual calls to …

7 - 60 years of age All Phase N/A
L Leila Yazdanbakhsh

Pathobiomes in Gut of Critically Ill Patients

Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain unknown. Many patients who survive the initial surgical trauma still succumb to multi-organ failure and septicemia secondary to an …

18 - 85 years of age All Phase N/A
L Lorie Cashdollar, BA

Mindfulness, Exercise, and Nutrition To Optimize Resilience (MENTOR)

The Mindfulness, Nutrition and Exercise to Optimize Resilience (MENTOR) program is offered through the National Center on Health, Physical Activity and Disability (NCHPAD). NCHPAD is funded by the Centers for Disease Control and Prevention (CDC), is a public health practice that offers health promotion programs and resources to people with …

18 years of age All Phase N/A
S Site Public Contact

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period …

18 years of age All Phase 2

Simplify language using AI